THPdb2: compilation of FDA approved therapeutic peptides and proteins
- PMID: 38830503
- DOI: 10.1016/j.drudis.2024.104047
THPdb2: compilation of FDA approved therapeutic peptides and proteins
Abstract
During the past 20 years, there has been a significant increase in the number of protein-based drugs approved by the US Food and Drug Administration (FDA). This paper presents THPdb2, an updated version of the THPdb database, which holds information about all types of protein-based drugs, including peptides, antibodies, and biosimilar proteins. THPdb2 contains a total of 6,385 entries, providing comprehensive information about 894 FDA-approved therapeutic proteins, including 354 monoclonal antibodies and 85 peptides or polypeptides. Each entry includes the name of therapeutic molecule, the amino acid sequence, physical and chemical properties, and route of drug administration. The therapeutic molecules that are included in the database target a wide range of biological molecules, such as receptors, factors, and proteins, and have been approved for the treatment of various diseases, including cancers, infectious diseases, and immune disorders.
Keywords: Biosimilar proteins; FDA-approved drugs; Knowledgebase; Monoclonal antibodies; Peptide therapeutics; Protein-based drugs.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Similar articles
-
THPdb: Database of FDA-approved peptide and protein therapeutics.PLoS One. 2017 Jul 31;12(7):e0181748. doi: 10.1371/journal.pone.0181748. eCollection 2017. PLoS One. 2017. PMID: 28759605 Free PMC article.
-
'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.Adv Ther. 2024 May;41(5):1795-1814. doi: 10.1007/s12325-024-02809-w. Epub 2024 Mar 21. Adv Ther. 2024. PMID: 38514505 Free PMC article. Review.
-
Comparing Onset of Biosimilar Versus Generic Competition in the United States.Clin Pharmacol Ther. 2020 Dec;108(6):1308-1314. doi: 10.1002/cpt.1981. Epub 2020 Aug 17. Clin Pharmacol Ther. 2020. PMID: 32621540
-
Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.JCO Oncol Pract. 2023 Nov;19(11):1053-1057. doi: 10.1200/OP.23.00309. Epub 2023 Sep 22. JCO Oncol Pract. 2023. PMID: 37738533
-
The US Biosimilar Market: Stunted Growth and Possible Reforms.Clin Pharmacol Ther. 2019 Jan;105(1):92-100. doi: 10.1002/cpt.1285. Epub 2018 Dec 28. Clin Pharmacol Ther. 2019. PMID: 30415479 Review.
Cited by
-
AAGP integrates physicochemical and compositional features for machine learning-based prediction of anti-aging peptides.Sci Rep. 2025 Aug 8;15(1):29036. doi: 10.1038/s41598-025-12759-0. Sci Rep. 2025. PMID: 40781463 Free PMC article.
-
cyclicpeptide: a Python package for cyclic peptide drug design.Brief Bioinform. 2024 Nov 22;26(1):bbae714. doi: 10.1093/bib/bbae714. Brief Bioinform. 2024. PMID: 39783893 Free PMC article.
-
Prediction of hemolytic peptides and their hemolytic concentration.Commun Biol. 2025 Feb 4;8(1):176. doi: 10.1038/s42003-025-07615-w. Commun Biol. 2025. PMID: 39905233 Free PMC article.
-
CancerPPD2: an updated repository of anticancer peptides and proteins.Database (Oxford). 2025 May 7;2025:baaf030. doi: 10.1093/database/baaf030. Database (Oxford). 2025. PMID: 40338521 Free PMC article.
-
Design of nanobody targeting SARS-CoV-2 spike glycoprotein using CDR-grafting assisted by molecular simulation and machine learning.PLoS Comput Biol. 2025 Apr 21;21(4):e1012921. doi: 10.1371/journal.pcbi.1012921. eCollection 2025 Apr. PLoS Comput Biol. 2025. PMID: 40257976 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous